Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 244-182-1 | CAS number: 21056-98-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute toxicity potential of calcium hydrogen phosphonate was evaluated by oral route only. The oral LD50 is higher than 2000 mg/kg in rat. No data is available by dermal and inhalation route.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 07 January 2016- 30 June 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: breeder: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: 8 weeks old at the beginning of the study
- Mean body weight at study initiation: 191.5 g (range: 176 g to 210 g)
- Fasting period before study: yes, during the night before treatment
- Housing: the animals were housed in threes from the same group in polycarbonate cages with stainless steel lids
- Diet: foodstuff (A04, SAFE) (free access)
- Water: tap water (free access)
- Acclimation period: at least 5 days before the beginning of the study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 25°C
- Humidity (%):30 to 70%
- Air changes (per hr):at least 10 cycles/hour
- Photoperiod (hrs dark / hrs light): 12 h/12 h.
IN-LIFE DATES: 19 January 2016 to 03 February 2016. - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 200 mg/mL
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg
DOSAGE PREPARATION (if unusual): the test item was weighed and distilled water was added to a 10 mL volumetric flask. the preparations were stirred by vortex to obtain white solutions just before the administration.
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 3 females
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Clinical observations: frequently during the hours following treatment; then, at least once a day.
- Body weight: just before treatment on day 0; then on days 2, 7 and 14.
- Necropsy of survivors performed: yes (macroscopic). - Statistics:
- no
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mL/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no death
- Mortality:
- No unscheduled deaths occurred during the study.
- Clinical signs:
- No clinical signs related to the administration of the test item were observed during the study.
- Body weight:
- The body weight evolution of the animals remained normal during the study.
- Gross pathology:
- The macroscopic examination of the animals at the end of the study did not reveal treatment related changes.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The oral LD50 of calcium hydrogen phosphonatewas higher than 2000 mg/kg in rats.
- Executive summary:
The objective of this study was to evaluate the potential acute toxicity of the test item calcium hydrogen phosphonate following a single oral administration (gavage) to rats. This study was conducted in compliance with OECD Guideline No. 423 and the principles of Good Laboratory Practices. The test item was administered once by oral route (gavage) to three fasted female Sprague-Dawley rats at 2000 mg/kg under a dosage-volume of 10 mL/kg in distilled water. Each animal was observed at least once a day for mortality and clinical signs for 14 days. Body weight was recorded on Day 0 and then on Days 2, 7 and 15. On completion of the observation period, the animals were sacrificed and then submitted for a macroscopic post-mortem examination.
No unscheduled deaths occurred during the study and no clinical signs were observed in animals. Body weight was unaffected by the test item treatment. There were no test item-related gross findings.
Therefore, the oral LD50 of the test item was considered to be higher than 2000 mg/kg in rats and no classification as toxic by oral route according to the criteria of CLP Regulation was required.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The key study is considered to be reliable with a klimish score of 1.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute toxicity by oral route :
The objective of this study was to evaluate the potential acute toxicity of the test item calcium hydrogen phosphonate following a single oral administration (gavage) to rats. This study was conducted in compliance with OECD Guideline No. 423 and the principles of Good Laboratory Practices. The test item was administered once by oral route (gavage) to three fasted female Sprague-Dawley rats at 2000 mg/kg under a dosage-volume of 10 mL/kg in distilled water. Each animal was observed at least once a day for mortality and clinical signs for 14 days. Body weight was recorded on Day 0 and then on Days 2, 7 and 15. On completion of the observation period, the animals were sacrificed and then submitted for a macroscopic post-mortem examination.
No unscheduled deaths occurred during the study and no clinical signs were observed in animals. Body weight was unaffected by the test item treatment. There were no test item-related gross findings.
Therefore, the oral LD50 of the test item was considered to be higher than 2000 mg/kg in rats.
Justification for classification or non-classification
Based on the available data, the criteria of classification were not filled. According to the Regulation EC n°1272/2008, no classification for acute toxicity is required for calcium hydrogen phosphonate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.